Get the Stockscreener App
1.56
1.27%
-0.02
After Hours:
1.58
0.02
+1.28%
Opko Health Inc stock is traded at $1.56, with a volume of 1.44M.
It is down -1.27% in the last 24 hours and up +7.59% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
See More
Previous Close:
$1.58
Open:
$1.57
24h Volume:
1.44M
Relative Volume:
0.41
Market Cap:
$1.08B
Revenue:
$863.49M
Net Income/Loss:
$-188.86M
P/E Ratio:
-5.7778
EPS:
-0.27
Net Cash Flow:
$-44.47M
1W Performance:
-3.70%
1M Performance:
+7.59%
6M Performance:
+20.00%
1Y Performance:
+3.65%
1-Day Range:
$1.56
$1.585
1-Week Range:
$1.55
$1.68
52-Week Range:
$0.8516
$1.745
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| OPK | 1.56 | 1.08B | 863.49M | -188.86M | -44.47M | -0.27 |
| TMO | 516.10 | 196.16B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 235.05 | 167.17B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 132.06 | 37.94B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 197.60 | 35.86B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 418.55 | 34.27B | 3.84B | 866.24M | 792.60M | 9.80 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
OPKO Health (OPK) Q3 Earnings Surpass Estimates - MSN
Hyperparathyroidism Treatment Market Growth Trends, Regional - openPR
NextPlat to Showcase OPKO Healthcare Products at Major Chinese Health Expo | NXPLW Stock News - StockTitan
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts - MSN
OPKO Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Opko health CEO Phillip Frost buys $161,980 in stock - Investing.com
Rubric Capital Management LP's Strategic Acquisition in OPKO Hea - GuruFocus.com
Barrington Research Estimates OPKO Health FY2028 Earnings - MarketBeat
Insider Buying: OPKO Health Chairman & CEO Bought US$422k Of Shares - Simply Wall St
Phillip Frost Buys Handful Of Shares In OPKO Health - Yahoo Finance
OPKO Health: Q3 Earnings Snapshot - AOL
OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 280,183 Shares - MarketBeat
OPKO Health's (OPK) Outperform Rating Reiterated at Barrington Research - MarketBeat
OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Simply Wall St
OPKO Health, Inc. (NASDAQ:OPK) Q3 2024 Earnings Call Transcript - Insider Monkey
OPKO Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
Opko health CEO Phillip Frost purchases $421,535 in stock By Investing.com - Investing.com Nigeria
Opko health CEO Phillip Frost purchases $421,535 in stock - Investing.com India
Earnings call: OPKO Health Q3 2024 results show promise amid challenges - Investing.com
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates - StockTitan
OPKO Health Shows Strategic Progress in Q3 2024 - TipRanks
Opko Health (OPK) Q3 2024 Earnings Call Transcript - AOL
Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings - Yahoo Finance
Opko Health earnings beat by $0.12, revenue fell short of estimates - Investing.com Canada
OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results - The Manila Times
Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch® - The Manila Times
Aspira Women’s Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch® - Yahoo Finance
Health Check-up Market is Expected to Soar in the Upcoming Years - openPR
OPKO Health, Inc. (NASDAQ:OPK) Shares Bought by Assenagon Asset Management S.A. - MarketBeat
OPKO Health (OPK) Set to Announce Earnings on Thursday - MarketBeat
Head to Head Review: OPKO Health (NASDAQ:OPK) vs. OptiNose (NASDAQ:OPTN) - Defense World
OPKO Health, Inc.'s (NASDAQ:OPK) CEO Phillip Frost is the most upbeat insider, and their holdings increased by 9.6% last week - Simply Wall St
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - MSN
OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times
Opko Health Inc (OPK-Q) QuotePress Release - The Globe and Mail
OPKO Health (NASDAQ:OPK) Trading 4.7% HigherShould You Buy? - MarketBeat
SECONDARY HYPERPARATHYROIDISM MARKET TO WITNESS UPSURGE - openPR
Us Prostate Cancer Instruments And Test Market Report: - openPR
With 50% ownership, OPKO Health, Inc. (NASDAQ:OPK) insiders have a lot riding on the company's future - Yahoo Finance
Hypopituitarism Market Forecasted to Surge in Coming Years, - openPR
GeneDx (NASDAQ:WGS) Reaches New 52-Week HighTime to Buy? - MarketBeat
35,157 Shares in OPKO Health, Inc. (NASDAQ:OPK) Bought by Algert Global LLC - Defense World
Renaissance Technologies LLC Cuts Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies - MSN
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):